Why Candel Therapeutics, Inc.’s (CADL) Stock Is Down 5.41%
As of Tuesday, September 29, Candel Therapeutics, Inc.’s CADL share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Commentary & Analysis
Why Candel Therapeutics, Inc.’s (CADL) Stock Is Up 6.36%
As of Monday, September 21, Candel Therapeutics, Inc.’s CADL share price has surged by 6.36%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Candel Therapeutics, Inc.’s (CADL) Stock Is Down 9.00%
As of Friday, September 11, Candel Therapeutics, Inc.’s CADL share price has dipped by 9.00%, which has investors questioning if this is right time to buy.Michael Rose
Why Candel Therapeutics, Inc.’s (CADL) Stock Is Down 5.01%
As of Thursday, September 10, Candel Therapeutics, Inc.’s CADL share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Candel Therapeutics, Inc.’s (CADL) Stock Is Up 5.75%
As of Tuesday, August 25, Candel Therapeutics, Inc.’s CADL share price has surged by 5.75%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CADL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $760.6 | $242.6 | 42% |
|
| Shares Out (Mil) | 74.1 | 54.0 | 56% |
|
| Institutional Ownership | 88.8% | 93.1% | 57% |
|
| Float (Mil) | 60.2 | 41.4 | 51% |
|
| Beta | -0.50 | 0.95 | 2% |
|
| Avg Daily Volume (000s) | 920 | 633 | 68% |
|
| Price Change (52-week) |
57.8% | 50.0% | 87% |
|
| Growth | CADL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (16.6%) | (10.1%) | 24% |
|
| EPS (5yr) | 13.9% | 15.8% | 54 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (33.7%) | (15.7%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 3 | 2 | |
| Current EPS | ($0.310) | ($1.080) | ($0.625) | |
| Month Ago EPS | ($0.310) | ($1.003) | ($0.625) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 3 | 2 | 1 | |
| Three Months Ago EPS | ($0.260) | ($0.873) | $0.220 | |
| Year/Year Chg | (41.0%) | 49.8% | (12.6%) | |
| Financials | CADL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($89) | ($44) | 12% |
|
| EPS (TTM) | ($1.437) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($56) | ($34) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $101 | $2 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $49 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $889 | $177 | 39% |
|
| Valuation | CADL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.99 | 2.33 | 83% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CADL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (56.4%) | (47.6%) | 10% |
|
| ROE | (81.8%) | (54.9%) | 11% |
|
| Liabilities to Assets | 39.4% | 29.3% | 30% |
|
| F-Score | 2 | 3 | 7% |
|
Candel Therapeutics, Inc. did not pass any screens on 10/9/2026.
